Retatrutide conferred weight loss of greater than 20% for adults with obesity and type 2 diabetes, as well as those with severe obesity and established cardiovascular disease, according to topline results from two phase 3 trials.
As Healio previously reported from the TRIUMPH-1 trial, adults with obesity without diabetes achieved weight loss of up to 25% at 80 weeks with once-weekly retatrutide (Eli Lilly). In new findings from the TRIUMPH-2 and TRIUMPH-3 trials, Eli Lilly and Co. reported that the novel medication also induced significant weight loss for adults with obesity and other

In this Nourish to Flourish column, Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Nina Crowley, PhD, RDN, LD, about why body composition, nutrition and communication are central to quality care in the GLP-1 era.
The interview also focuses on how clinicians can prioritize meaningful measures to improve outcomes.
Weiner: As obesity pharmacotherapy becomes more effective, why is scale weight alone no longer an adequate marker of treatment success?
Crowley: For decades, weight has been treated as the primary outcome in obesity care. However, weight on the scale does not equal health. It

A 46-year-old woman with hypothyroidism and prior substance use disorder presented to the emergency department with a 1-week history of left eye blurry vision and floaters.
Four weeks before presentation, she developed a pruritic rash that began on her thighs and spread to involve the trunk and scalp before further extending distally (Figure 1). Around the time of the rash’s onset, she developed diffuse arthralgias and patchy hair loss. The patient also endorsed bilateral periorbital pruritus, epiphora and photophobia. In the past 2 weeks, she also experienced morning headaches alleviated by

Limbal stem cell deficiency is an underrecognized but potentially devastating condition of the ocular surface.
Although not the most common diagnosis, it is certainly not rare, and its ability to masquerade as more routine ocular surface disease can make it easy to miss. Determining the right treatment plan for a patient with limbal stem cell deficiency (LSCD) hinges on accurate diagnosis and staging, so vigilance and flexibility are key to successfully managing this condition (Lent-Schochet et al.).
At its core, LSCD is a failure of the limbal stem cells to maintain and regenerate the corneal

This 94-year-old patient presents with cataracts and pseudoexfoliation syndrome, with the right eye having more stability and the left having less, as seen in Figure 1.
Given that the patient is a nonagenarian, the ocular structural tissues are already fragile. When you combine that with the progressive zonular weakness of pseudoexfoliation, the risk for intraoperative capsular bag loss, pseudophacodonesis or postoperative IOL dislocation escalates dramatically.
The patient first had successful cataract surgery of the right eye, which had less pseudoexfoliation fibrillar material and better

Welcome back to Meibomian Gland Adventure Land! Last month, I offered a basic definition of “best practices” vs. standard of care and then applied it to making the diagnosis of MGD. This month’s task is to do the same thing with treatment.
To review, evaporative dry eye disease (eDED) likely represents upward of 80% of diagnosable DED in the U.S. The underlying pathophysiology is either low-quantity or low-quality meibomian gland secretions, or both. This, with or without other causative contributors such as infrequent or inadequate blinking, results in an increase in the rate of tear

KIAWAH ISLAND, S.C. — In this video from Kiawah Eye & Retina, Kourtney H. Houser, MD, highlights the benefits of Lacrifill from Nordic Pharma in neurotrophic keratitis.
“There’s a new technology called Lacrifill that I haven’t been able to use yet, but I have lots of colleagues that have, and I’ve learned about from this meeting, where we can get a more complete closure of the punctum for longer duration, 3 to 6 months, than some of our other punctal plugs can offer. And it’s comfortable for patients to apply,” Houser, of Duke Eye Center, said. “I’m excited about implementing this in

Adults with chronic migraine had greater odds for gastrointestinal comorbidities than those with no migraine, according to an abstract presented at the American Headache Society 68th Annual Scientific Meeting.
“Previous work has shown that migraine is associated with several GI disorders, but the full scope has been underexplored,” Leon S. Moskatel, MD, clinical assistant professor of adult neurology at Stanford Medicine, told Healio. “We thought it was important to examine a full spectrum of GI disorders in patients with chronic migraine.”
The retrospective observational cohort study included

The dermatology community has long debated whether dupilumab treatment for atopic dermatitis is associated with the development of cutaneous T-cell lymphoma — a concern that becomes more urgent when children are involved.
In 2024, a retrospective cohort study suggested that dupilumab (Dupixent; Sanofi, Regeneron) was associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for AD. However, it remained unclear whether dupilumab caused the disease or simply unmasked existing cases, Healio previously reported.
“Dupilumab has been a tremendous breakthrough

Ann H. Partridge, MD, MPH, still remembers her patient’s anger 25 years later.
Partridge, founder and director of the Young and Strong Program for Young Adults with Breast Cancer at Dana-Farber Cancer Institute, was treating a young woman with breast cancer who was “distraught” she would potentially not be able to have a baby.
In 2001, clinicians had concerns pregnancy would lead to worse disease outcomes, including recurrence.
The patient, “mad at the world,” became more enraged seeing Partridge, who had her own baby bump at the time.
“I was the messenger, and I was pregnant,” Partridge